← Back to Directory

Legend Biotech Corporation (LEGN) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for Legend Biotech Corporation (LEGN).

Download StockRank on Google Play Download StockRank on the App Store

Equity Details

Price & Market Data

Price: $28.00

Daily Change: +$2.42 / 8.64%

Daily Range: $24.30 - $28.35

Market Cap: $5,249,006,592

Daily Volume: 5,050,401

Performance Metrics

1 Week: -0.88%

1 Month: 59.75%

3 Months: 57.79%

6 Months: -11.13%

1 Year: -12.72%

YTD: 29.99%

About Legend Biotech Corporation (LEGN)

Dive into the latest financial snapshot of Legend Biotech Corporation (LEGN). With a current trading price of 28.00, the stock has experienced a daily shift of +$2.42 / 8.64%. The company's market capitalization stands impressively at 5,249,006,592. Track its year-to-date performance, which is at 29.99%, alongside its weekly, monthly, and yearly trends.

Company Details

Employees: 2900

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Selected stocks

Brinker International, Inc. (EAT)

Compass Therapeutics, Inc. (CMPX)

Groupon, Inc. (GRPN)

BioNTech SE (BNTX)

Alussa Energy Acquisition Corp. II (ALUB-UN)